Related Experiment Video

Updated: Jul 6, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from

Philippe L L'Allier1, Grégory Ducrocq, Nicolas Pranno

  • 1Department of Medicine, Montreal Heart Institute and Université de Montréal, Montreal, Quebec, Canada. philippe.lallier@icm-mhi.org

Journal of the American College of Cardiology
|March 18, 2008
PubMed

Insights

A double bolus of clopidogrel (600 mg twice) significantly enhances platelet inhibition compared to single loading doses. This regimen is superior for patients undergoing percutaneous coronary intervention.

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis

Background:

  • Optimal platelet inhibition is crucial for patients undergoing percutaneous coronary intervention (PCI).
  • The maximum absorbed dose of clopidogrel is typically 600 mg as a single bolus.
  • The efficacy of a double bolus regimen has not been previously described.

Purpose of the Study:

  • To compare the effectiveness of three different clopidogrel loading regimens.
  • To assess the level of platelet inhibition in patients undergoing elective angiography and PCI.

Main Methods:

  • 148 patients were randomized into three groups receiving different clopidogrel loading doses.
  • Group A: 300 mg pre-procedure + 75 mg on procedure day.
  • Group B: 600 mg on procedure day.
  • Group C: 600 mg pre-procedure + 600 mg on procedure day.
  • Platelet aggregation was measured pre-angiography.

Main Results:

  • Group C demonstrated significantly higher peak and late platelet inhibition compared to Groups A and B.
  • Peak platelet inhibition was 49.5% in Group C versus 31.4% (Group A) and 29.0% (Group B).
  • Late platelet inhibition was 81.1% in Group C versus 54.1% (Group A) and 57.7% (Group B).

Conclusions:

  • A 600-mg double bolus of clopidogrel significantly increases platelet inhibition.
  • This regimen is more effective than conventional single loading doses for PCI patients.
Abstract

More Related Videos

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...